Full Press Release Details
fianlimab lag 3 inhibitor combined with libtayo cemiplimab shows clinically meaningful and durable tumor responses across key advanced melanoma patient populations.
REGN
fianlimab lag 3 inhibitor combined with libtayo cemiplimab shows clinically meaningful and durable tumor responses across key advanced melanoma patient populations
Key Takeaway: fianlimab lag 3 inhibitor combined with libtayo cemiplimab shows clinically meaningful and durable tumor responses across key advanced melanoma patient populations